Mesenchymal Stem Cell Transport Liquid Carrier
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a method to maintain the viability and health of mesenchymal stem cells derived from the amniotic membrane of the umbilical cord during transport and storage, as these cells are typically not applied at the site of production and often experience a substantial time lapse between harvesting and utilization.
Innovation Solution
A liquid carrier comprising Trolox, Na+, K+, Cl−, H2PO4−, HEPES, Lactobionate, Sucrose, Mannitol, Glucose, Dextran-40, Adenosine, and Glutathione is used to transport and store mesenchymal stem cells, which helps in maintaining their viability and functionality.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If mesenchymal stem cells are harvested and stored for later use, then the cells can be transported to different locations and used in wound healing applications, but the viability and functionality of the cells deteriorate over time
Solution Approach 1:
The patent changes the chemical parameters of the storage medium by formulating a specific liquid carrier containing antioxidants (Trolox, glutathione), energy substrates (glucose, adenosine), and osmotic agents (sucrose, mannitol, dextran-40). This composition modification maintains cell viability during extended storage by creating an optimized chemical environment that prevents oxidative stress and energy depletion
Solution Approach 2:
The liquid carrier acts as an intermediary substance between the harvested stem cells and the wound site. It mediates the preservation of cell functionality during transport and storage, allowing the cells to remain viable and therapeutic without requiring immediate application to the wound
2Ease of operation
If mesenchymal stem cells are transported over time, then they can be administered at the wound site, but the cells lose their ability to secrete therapeutic factors and promote healing
Solution Approach 1:
The patent applies preliminary action by pre-formulating the liquid carrier with all necessary components (antioxidants, energy substrates, osmotic agents) before cell harvesting. This preliminary preparation ensures that when cells are transported and stored, they immediately have access to protective and nourishing factors that maintain their therapeutic functionality
Solution Approach 2:
The storage medium parameters are specifically modified to include Trolox (vitamin E analog), glutathione, adenosine, and dextran-40 at defined concentrations. These parameter changes create an environment that preserves both cell structure and secretory function, allowing cells to maintain their ability to produce therapeutic factors even after extended storage
Data Source
AI summary
The present invention relates to a method of transporting a stem cell population, the method comprising transporting the stem cell population contacted with a liquid carrier. In addition, the present invention concerns a method of treating a subject having a disease, the method comprising topically administering a defined mesenchymal stem cell population to the subject, wherein the mesenchymal stem cell population is administered within about 96 hours from the time point the mesenchymal stem cell population has been harvested. Also concerned is a unit dosage comprising about 20 million cells, of about 15 million cells, of about 10 million cells, of about 5 million cells, of about 4 million cells, of about 3 million cells, of about 2 million cells, of about 1 million cells, of about 0.5 million cells, of about 0.25 million cells or of less than 0.25 million cells of a defined mesenchymal stem cell population.